Stay updated on Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial
Sign up to get notified when there's something new on the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page.

Latest updates to the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page
- Check7 days agoChange DetectedThe web page has updated its version from v2.15.0 to v2.15.2 and has removed older dates from March 2025, replacing them with newer dates in April 2025.SummaryDifference0.3%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant changes, including the removal of detailed information about a clinical study evaluating daratumumab for multiple myeloma, while adding new drug names and identifiers related to the study.SummaryDifference17%
- Check29 days agoChange DetectedThe page has been updated to reflect the latest version as v2.14.4, replacing the previous version v2.14.3. The estimated last update posted has been removed.SummaryDifference0.1%
- Check37 days agoChange DetectedThe page has updated its version from v2.14.2 to v2.14.3 and has added new dates for March and April 2025 while removing previous dates from February 2025.SummaryDifference0.3%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.7%
- Check80 days agoChange DetectedThe webpage has updated its content to reflect new dates and locations, replacing previous entries with more recent information. Notably, the last update date has changed from May 2024 to February 2025.SummaryDifference0.8%
Stay in the know with updates to Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Subcutaneous Daratumumab With Standard Myeloma Regimens Clinical Trial page.